Clinical Sample Collection COVID19 Patients to Align with NIAID National Study

  • Funded by National Institutes of Health (NIH)
  • Total publications:1 publications

Grant number: 3R01AI141953-02S1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $309,206
  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

    Pending
  • Research Location

    United States of America, Americas
  • Lead Research Institution

    INSTITUTE FOR SYSTEMS BIOLOGY
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The NIAID national protocol intends to enroll at least 1000 COVID19 patients in a study designed to track infectedpatients through tracking, over time, their immune responses, viral load, and a variety of multi-omic analytes thatcan provide deep insights into how infection by SARS-CoV-2 is revealed in host defense responses and disease-perturbed networks. At the heart of this study is the establishment of high quality biorepositories that can beused to quantitatively assess viral load, quantitatively interrogate viable PBMCs, and permit direct comparisonsbetween different patients and different time points of disease progression. The nature of the infection, withhighly differential patient outcomes, will eventually require significant computational efforts that can account forconfounding factors such as co-morbidities, the influence of various therapies that are being broadly tested inthese patients, etc. It will also almost certainly require all 1000 projected patients, if not more, to resolve someof the most outstanding and urgent clinical questions. However, all of these results rely on establishing highquality biobanks, resource sharing, and data sharing. This is an area in which the ISB has deep expertise andis excited to contribute. The ISB and SMC launched a joint study designed to enroll 200 COVID19 patientsaround 3/20/2020. That study has overlap with the NIAID protocol and shares a common set of over-archinggoals. Here we propose to increase that overlap and to make that accruing biobank of COVID19 patientspecimens and associated characterization data a national resource through inclusion in the NIAID protocol.

Publicationslinked via Europe PMC

Last Updated:40 minutes ago

View all publications at Europe PMC

Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae.